In Shymkent, the expansion of Polpharma Santo's pharmaceutical production facility is planned, backed by 39.5 billion tenge in private investments. The relevant investment agreement between the Ministry of Healthcare of the Republic of Kazakhstan and JSC Khimpharm has been approved by the government and signed by Prime Minister Olzhas Bektenov.
The project focuses on constructing new production facilities and advancing scientific research in the pharmaceutical sector. Approximately 300 new jobs are expected to be created. The launch of the first production phase is scheduled for late 2029.
Once operating at full capacity, the facility will be able to manufacture 38 types of pharmaceutical products intended for the treatment of oncological, cardiovascular, infectious, and chronic diseases, as well as tuberculosis. Production will comply with international quality standards.
The government emphasizes that implementing this project will strengthen the country's pharmaceutical security, improve medication accessibility for the population, and enhance the export potential of Kazakhstan's pharmaceutical industry.
To date, six investment agreements totaling 316.3 billion tenge have been concluded within Kazakhstan's pharmaceutical sector. Authorities expect these initiatives to accelerate production localization and reduce dependence on imported medicines.
Source: POLITES NEWS
